Drotrecogin Alfa (Activated) in Adults with Septic Shock

20121,272 citationsJournal Articlegreen Open Access

Authors

V. Marco Ranieri · Université Paris Cité

Bruce Thompson · Massachusetts General Hospital

Philip S. Barie · Université Paris Cité

Jean-François Dhainaut · Université Paris Cité

Ivor S. Douglas · Universitat Autònoma de Barcelona

Simon Finfer · Universitat Autònoma de Barcelona

Bengt Gårdlund

Abstract

DrotAA did not significantly reduce mortality at 28 or 90 days, as compared with placebo, in patients with septic shock. (Funded by Eli Lilly; PROWESS-SHOCK ClinicalTrials.gov number, NCT00604214.).

Topics & Keywords

Sepsis Diagnosis and Treatment Clusterin in disease pathology Hyperglycemia and glycemic control in critically ill and hospitalized patients

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 366, Issue 22, pp. 2055-2064

DOI: 10.1056/nejmoa1202290

Field-Weighted Citation Impact: 96.33